Cullinan & Taiho Target NSCLC Filing, Maintenance Emerges in SCLC, Innate’s Antibody Sustains Lymphoma Benefit

Cullinan and Taiho Reveal Positive NSCLC Data Ahead of FDA Filing

Context: Cullinan Oncology and Taiho are developing CLN-081, an EGFR exon 20 insertion–targeting therapy for NSCLC—a mutation subtype with limited approved options.

What's New? At ASCO, the companies presented data showing a response rate of 41% and a 12.7-month median duration of response for CLN-081. The results are expected to support an FDA submission in the second half of 2024.

Why it Matters? These findings position CLN-081 as a potential new treatment standard in exon 20-mutant NSCLC, addressing a high unmet need with a differentiated safety profile.

Maintenance Strategy Shows Promise in Extensive-Stage Small Cell Lung Cancer

Context: Maintenance therapy has not historically played a major role in extensive-stage small cell lung cancer (ES-SCLC), where prognosis remains poor.

What's New? New trial results presented at ASCO support the addition of maintenance chemotherapy and immunotherapy as a potential new treatment paradigm, improving overall survival in ES-SCLC patients.

Why it Matters? These data could shift clinical practice toward maintenance approaches in SCLC, providing a needed advance in a disease with limited long-term treatment strategies.

Innate’s Anti-KIR3DL2 Antibody Shows Long-Term Activity in T-Cell Lymphoma

Context: KIR3DL2 is a novel immune target expressed in certain T-cell lymphomas, including Sézary syndrome and cutaneous T-cell lymphoma (CTCL).

What's New? At ASCO, Innate Pharma presented long-term data for its antibody lacutamab, showing sustained responses and durable disease control over 2 years in advanced CTCL patients.

Why it Matters? The findings support KIR3DL2 inhibition as a meaningful treatment option in rare T-cell lymphomas and strengthen the case for further development of lacutamab in hematologic cancers.

Study Strengthens Link Between PCOS and Endometrial Cancer

Context: Polycystic ovary syndrome (PCOS) has been associated with metabolic abnormalities and hormonal imbalances, but its cancer risk implications are still being clarified.

What's New? A new population study found that women with PCOS have a significantly increased risk of developing endometrial cancer, reinforcing the need for early gynecologic monitoring in this population.

Why it Matters? These findings may influence screening practices and long-term risk management in PCOS patients, especially in reproductive-age women with persistent hormonal dysregulation.

Oncology Hero

Cullinan & Taiho Target NSCLC Filing, Maintenance Emerges in SCLC, Innate’s Antibody Sustains Lymphoma Benefit

Cullinan and Taiho Reveal Positive NSCLC Data Ahead of FDA Filing

Maintenance Strategy Shows Promise in Extensive-Stage Small Cell Lung Cancer

Innate’s Anti-KIR3DL2 Antibody Shows Long-Term Activity in T-Cell Lymphoma

Study Strengthens Link Between PCOS and Endometrial Cancer

8 new oncology trials approved in Europe

15 new oncology trials approved in Europe

6 new oncology trials approved in Europe